NEONC TECHNOLOGIES HOLDINGS, INC.
NTHINasdaq
$3.46
↑ +6.5%Jul 17 close · end-of-day
Price
1Y↓ -19.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$80.6M
Enterprise Value
$80.5M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$38.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
292.0%
ROIC
—
Debt / Equity
—
Net Cash
$138,601.00
Return 1Y
-21.5%
Company profile
Our company was formed in 2008, devoted to developing new drugs with new delivery modes. NeOnc Technologies, Inc. was incorporated in Delaware in 2008 as NAS-ONC, Inc. In April 2023, shareholders of NeOnc Technologies, Inc. completed a share exchange (the “Share Exchange”) with NeOnc Technologies Holdings, Inc. pursuant to which all shareholders of NeOnc Technologies, Inc. became shareholders of NeOnc Technologies Holdings, Inc. and NeOnc Technologies, Inc. became a wholly-owned subsidiary of NeOnc Technologies Holdings, Inc. Our executive offices are located at 2 Dole Drive, Westlake Village, CA.
- CEO
- Thomas C. Chen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- neonctech.com
Management & directors
- Heshmatpour Amir FPresident
- Neman-Ebrahim YoushaChief Clinical Officer
- Suh, David Jr.Chief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
NTHI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.38↓ -78.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | $83,000.00 | $39,990.00 |
| Gross profit | — | — |
| Operating income | -$7.1M | -$58.2M |
| Net income | -$11.9M | -$62.1M |
| Diluted EPS | -$0.69 | -$3.20 |
| Operating cash flow | -$4.2M | -$20.4M |
| Free cash flow | — | — |
| Gross margin | — | — |
| Operating margin | -8605.4% | -145637.5% |
| Net margin | -14335.5% | -155404.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20,000.00 | $0.00 | $20,000.00 | $39,990.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.3M | -$2.2M | -$2.1M | -$31.9M | -$5.7M | -$6.9M | -$13.7M | -$7.1M |
| Net income | -$4.5M | -$2.2M | -$2.3M | -$32.3M | -$5.7M | -$8.6M | -$15.5M | -$8.8M |
| Diluted EPS | -$0.27 | -$0.12 | -$0.12 | -$1.78 | -$0.30 | -$0.45 | -$0.67 | -$0.38 |
| Operating cash flow | -$318,203.00 | -$3.1M | -$954,404.00 | -$5.7M | -$5.3M | -$5.8M | -$3.6M | -$7.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -6400.6% | — | -10568.7% | -79772.0% | — | — | — | — |
| Net margin | -22610.0% | — | -11264.9% | -80835.2% | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-01 | Heshmatpour Amir F· President | Buy | 10,000 | $4.16 | $41,592.00 | filing |
| 2026-04-28 | Heshmatpour Amir F· President | Buy | 10,000 | $4.52 | $45,180.00 | filing |
| 2026-04-23 | Heshmatpour Amir F· President | Buy | 10,000 | $4.90 | $49,000.00 | filing |
| 2026-04-23 | Neman-Ebrahim Yousha· Chief Clinical Officer | Buy | 500 | $4.88 | $2,440.00 | filing |
| 2026-04-10 | Heshmatpour Amir F· President | Buy | 10,000 | $4.90 | $48,950.00 | filing |
| 2026-04-09 | Heshmatpour Amir F· President | Buy | 5,000 | $5.19 | $25,950.00 | filing |
| 2026-04-09 | SUH, DAVID JR.· Chief Accounting Officer | Buy | 200 | $5.00 | $1,000.00 | filing |
| 2026-04-08 | Heshmatpour Amir F· President | Buy | 10,000 | $5.61 | $56,050.00 | filing |
| 2026-04-06 | Heshmatpour Amir F· President | Buy | 5,000 | $6.32 | $31,600.00 | filing |
| 2026-04-02 | Heshmatpour Amir F· President | Buy | 20,000 | $6.09 | $121,798.00 | filing |
| 2026-03-01 | SUH, DAVID JR.· Chief Accounting Officer | Award | 111,666 | — | — | filing |
| 2025-11-24 | Heshmatpour Amir F· President | Buy | 6,000 | $6.51 | $39,060.00 | filing |
| 2025-11-21 | Heshmatpour Amir F· President | Buy | 20,000 | $5.98 | $119,600.00 | filing |
| 2025-11-21 | Heshmatpour Amir F· President | Buy | 4,000 | $6.50 | $26,000.00 | filing |
| 2025-11-20 | Neman-Ebrahim Yousha· Chief Clinical Officer | Buy | 1,100 | $6.69 | $7,359.00 | filing |
| 2025-11-06 | Heshmatpour Amir F· President | Award | 1,200,000 | — | — | filing |
| 2025-07-10 | SHOMALI NASIM | Award | 50,000 | — | — | filing |
Latest 17 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.